ReviewJournal of neurology2016
Myasthenia gravis: a clinical-immunological update.
Review in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.Journal of neurology · 2021Pooled it
- The Incidence of Childhood Thyrotoxicosis Is Increasing in Both Girls and Boys in Sweden.Hormone research in paediatrics · 2019Trial
- Trial
- Digital Monitoring of Patients with Generalized Myasthenia Gravis: A Prospective Pilot Study.Neurology and therapy · 2026Article
- Identification of Ocular and Systemic Predictors and Development of a Prediction Model in Ocular Myasthenia Gravis.Translational vision science & technology · 2026Article
- CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.Journal of neuroinflammation · 2026Review
- Diagnostic performance and safety of the edrophonium test in myasthenia gravis: a retrospective case-control study.Neurological research and practice · 2026Article
- Fracture Occurrence Within FRAX-Defined High-Risk Myasthenia Gravis: An Exploratory Stratification by Age and Activities of Daily Living.Journal of clinical medicine · 2026Article
- CAR-Cell Therapy for Autoimmune Diseases: From the Laboratory to Clinical Practice.Journal of immunology research · 2026Review
- Seropositive Myasthenia Gravis Triggered by Lyme Disease: A Case Study of Molecular Mimicry.Cureus · 2025Article
- Rehabilitation for functional enhancement of myasthenia gravis: A systematic review and meta-analysis.eNeurologicalSci · 2025Review
- The clinical characteristics and treatment response of myasthenia gravis with positive thyroid peroxidase antibody or thyroid globulin antibody.Journal of translational autoimmunity · 2025Article
- FcRn inhibitors for myasthenia gravis.The Cochrane database of systematic reviews · 2025Article
- Complement inhibitors for myasthenia gravis in adults.The Cochrane database of systematic reviews · 2025Article
- Unmasking Anti-CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments.European journal of neurology · 2025Article
- [Treatment and clinical course of autoimmune myasthenia in Burkina Faso].Medecine tropicale et sante internationale · 2025Article
- Myasthenia gravis in 2025: five new things and four hopes for the future.Journal of neurology · 2025Review
- Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018.PloS one · 2025Article
- Role of Nuclear Envelope Proteins in the Structure and Function of the Neuromuscular Junction: Focus on Subsynaptic Nuclei.Sub-cellular biochemistry · 2025Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is the archetypic disorder of both the neuromuscular junction and autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine receptors cause fatigable weakness of skeletal muscles. In the rest, a variable proportion possesses antibodies to muscle-specific tyrosine kinase while the remainder of seronegative MG is being explained through cell-based assays using a receptor-clustering technique and, to a lesser extent, proposed new antigenic targets. The incidence and prevalence of MG are increasing, particularly in the elderly. New treatments are being developed, and results from the randomised controlled trial of thymectomy in non-thymomatous MG, due for release in early 2016, will be of particular clinical value. To help navigate an evidence base of varying quality, practising clinicians may consult new MG guidelines in the fields of pregnancy, ocular and generalised MG (GMG). This review focuses on updates in epidemiology, immunology, therapeutic and clinical aspects of GMG in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.